Cargando…
Correction: Biomarkers and overall survival in patients with advanced hepatocellular carcinoma treated with TGF-βRI inhibitor galunisertib
| Formato: | Online Artículo Texto |
|---|---|
| Lenguaje: | English |
| Publicado: |
Public Library of Science
2020
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7316286/ https://www.ncbi.nlm.nih.gov/pubmed/32584902 http://dx.doi.org/10.1371/journal.pone.0235580 |
| _version_ | 1783550407632486400 |
|---|---|
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-7316286 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2020 |
| publisher | Public Library of Science |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-73162862020-06-30 Correction: Biomarkers and overall survival in patients with advanced hepatocellular carcinoma treated with TGF-βRI inhibitor galunisertib PLoS One Correction Public Library of Science 2020-06-25 /pmc/articles/PMC7316286/ /pubmed/32584902 http://dx.doi.org/10.1371/journal.pone.0235580 Text en © 2020 The PLOS ONE Staff http://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. |
| spellingShingle | Correction Correction: Biomarkers and overall survival in patients with advanced hepatocellular carcinoma treated with TGF-βRI inhibitor galunisertib |
| title | Correction: Biomarkers and overall survival in patients with advanced hepatocellular carcinoma treated with TGF-βRI inhibitor galunisertib |
| title_full | Correction: Biomarkers and overall survival in patients with advanced hepatocellular carcinoma treated with TGF-βRI inhibitor galunisertib |
| title_fullStr | Correction: Biomarkers and overall survival in patients with advanced hepatocellular carcinoma treated with TGF-βRI inhibitor galunisertib |
| title_full_unstemmed | Correction: Biomarkers and overall survival in patients with advanced hepatocellular carcinoma treated with TGF-βRI inhibitor galunisertib |
| title_short | Correction: Biomarkers and overall survival in patients with advanced hepatocellular carcinoma treated with TGF-βRI inhibitor galunisertib |
| title_sort | correction: biomarkers and overall survival in patients with advanced hepatocellular carcinoma treated with tgf-βri inhibitor galunisertib |
| topic | Correction |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7316286/ https://www.ncbi.nlm.nih.gov/pubmed/32584902 http://dx.doi.org/10.1371/journal.pone.0235580 |
| work_keys_str_mv | AT correctionbiomarkersandoverallsurvivalinpatientswithadvancedhepatocellularcarcinomatreatedwithtgfbriinhibitorgalunisertib |